This data strengthens BPL-003's profile ahead of Phase 3, supporting potential approval pathway. Traders should monitor for upcoming Part 4 data in Q4 2026 and formal Phase 3 trial launch in Q2 2026 as next catalysts. Despite recent insider selling, the clinical progress may attract institutional interest.
Price Chart
Executive Summary
AtaiBeckley announced positive Phase 2a results for BPL-003 in treatment-resistant depression, showing a 66.7% antidepressant response rate by Day 2 and durable responses through Week 12, with no serious adverse events. The drug has FDA Breakthrough Therapy Designation, and Phase 3 initiation is on track for Q2 2026.
Key Facts
- BPL-003 achieved 66.7% antidepressant response rate (≥50% MADRS reduction) by Day 2 in both 10 mg and 12 mg cohorts (n=12 total)
- Durable response at Week 12: 83% in 10 mg cohort, 66.7% in 12 mg cohort
- No serious adverse events reported; mean discharge time ~100 minutes post-dose
- FDA Breakthrough Therapy Designation granted October 2025
- Phase 3 initiation on track for Q2 2026 following End-of-Phase 2 meeting with FDA
Financial Impact
Non-dilutive clinical catalyst with high optionality value; de-risks Phase 3 initiation
Risk Factors
- Small trial size (n=12) limits statistical power
- Open-label design introduces bias risk
- Phase 3 may not replicate efficacy
- Regulatory hurdles remain despite Breakthrough designation
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269923 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 25-NSE | $7.30 awaiting T+20 | awaiting T+20 | — | — |
Aug 10, 2026 7w ago | DEFM14A | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Aug 9, 2026 7w ago | Institutional Cluster | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Jul 16, 2026 11w ago | DEFA14A / 8-K | $7.15 $7.25 | ▲ +1.40% | ▼ −2.22% | — |
Jul 7, 2026 12w ago | 144 | $5.17 $7.22 | ▲ +39.65% | ▲ +36.38% | — |
Jul 6, 2026 12w ago | Press Release | $4.96 $7.18 | ▲ +44.76% | ▲ +45.32% | — |
Jun 26, 2026 14w ago | 144 | $5.36 $7.18 | ▲ +33.96% | ▲ +34.23% | — |
Jun 25, 2026 14w ago | 144 | $5.29 $7.17 | ▲ +35.54% | ▲ +34.28% | — |
Jun 3, 2026 17w ago | 8-K | $4.53 $5.19 | ▲ +14.57% | ▲ +15.57% | — |
May 12, 2026 20w ago | Press Release | $4.15 $3.78 | ▼ −8.92% | ▼ −7.19% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access